HOME ·

SIMCERE PHARMA

SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China
Tags：
SIMCERE PHARMA02096.HKR&D Progress
2026-09-04
SIMCERE PHARMA(02096.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 828.72 million, YoY increase of 37.88%
Tags：
SIMCERE PHARMA02096.HKprofit growth
2026-08-21
SIMCERE PHARMA (02096.HK): Zhu Da appointed Joint Company Secretary succeeding Wan Yushan, waiver granted from company secretary qualification requirements
Tags：
SIMCERE PHARMA02096.HKBoard Change
2026-08-21
SIMCERE PHARMA (02096.HK): First-in-Class Innovative Drug Xibi Xin® (Edaravone and Dexborneol) Included in 2026 National Essential Medicines List
Tags：
SIMCERE PHARMA02096.HKPharmaceutical Updates
2026-07-09
SIMCERE PHARMA(02096.HK): PD-1/VEGF Bispecific Antibody SIM0689 Approved for Clinical Trials by NMPA
Tags：
SIMCERE PHARMA02096.HKClinicalTrialApproval
2026-06-12
SIMCERE PHARMA (02096.HK): SIM0613 (LRRC15 ADC) Receives NMPA Clinical Trial Approval
Tags：
SIMCERE PHARMA02096.HKClinicalTrialApproval
2026-05-06
SIMCERE PHARMA(02096.HK) will spend HKD 22.21 million to repurchase 1.88 million shares on Jan 20, 2026
Tags：
SIMCERE PHARMA02096.HK
2026-01-21